This would restore the possibility of immunotherapy in NSCLC patients with the expression of the discussed metalloproteinases in the case of progression during therapy with anti-PD-1 or anti-PD-L1 antibodies [12, 22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.